Neopharm Ltd Stock Current Liabilities
| 092730 Stock | KRW 12,000 90.00 0.74% |
NeoPharm LTD fundamentals help investors to digest information that contributes to NeoPharm's financial success or failures. It also enables traders to predict the movement of NeoPharm Stock. The fundamental analysis module provides a way to measure NeoPharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NeoPharm stock.
NeoPharm |
NeoPharm LTD Company Current Liabilities Analysis
NeoPharm's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current NeoPharm Current Liabilities | 6.06 B |
Most of NeoPharm's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NeoPharm LTD is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, NeoPharm LTD has a Current Liabilities of 6.06 B. This is much higher than that of the Personal Products sector and significantly higher than that of the Consumer Staples industry. The current liabilities for all Republic of Korea stocks is notably lower than that of the firm.
NeoPharm Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NeoPharm's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NeoPharm could also be used in its relative valuation, which is a method of valuing NeoPharm by comparing valuation metrics of similar companies.NeoPharm is currently under evaluation in current liabilities category among its peers.
NeoPharm Fundamentals
| Return On Equity | 13.82 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 153.58 B | |||
| Shares Outstanding | 7.99 M | |||
| Shares Owned By Insiders | 38.94 % | |||
| Shares Owned By Institutions | 17.81 % | |||
| Price To Earning | 42.54 X | |||
| Price To Sales | 1.56 X | |||
| Revenue | 87.93 B | |||
| Gross Profit | 58.64 B | |||
| EBITDA | 24.3 B | |||
| Net Income | 17.71 B | |||
| Cash And Equivalents | 7.05 B | |||
| Total Debt | 101.79 M | |||
| Debt To Equity | 0.60 % | |||
| Current Ratio | 4.20 X | |||
| Book Value Per Share | 4,777 X | |||
| Cash Flow From Operations | 21.68 B | |||
| Earnings Per Share | 576.00 X | |||
| Target Price | 36000.0 | |||
| Number Of Employees | 106 | |||
| Beta | 1.11 | |||
| Market Capitalization | 156.02 B | |||
| Total Asset | 143.41 B | |||
| Retained Earnings | 19.71 B | |||
| Working Capital | 16.77 B | |||
| Current Asset | 22.83 B | |||
| Current Liabilities | 6.06 B | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 143.41 B |
About NeoPharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NeoPharm LTD's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeoPharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeoPharm LTD based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in NeoPharm Stock
NeoPharm financial ratios help investors to determine whether NeoPharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NeoPharm with respect to the benefits of owning NeoPharm security.